Nathan Fuller

Nathan Fuller has worked in the pharmaceutical industry since 2005. Nathan began their career as a Post-Doctoral Research Associate at The University of Texas at Austin. In 2007, they joined Wyeth as a Senior Scientist, where they worked on a team in inflammation targeting MMP-12 inhibitors for the treatment of COPD and asthma. In 2009, they moved to Satori Pharmaceuticals as a Senior Research Scientist, contributing to the medicinal chemistry team for the Satori Gamma-Secretase Modulator program. In 2013, they joined AstraZeneca as a Senior Scientist, where they were an integral member of the newly created Fragment-Based Lead Generation (FBLG) Team. In 2015, they became the Senior Director of Chemistry and then the Director of Chemistry at Rodin Therapeutics. In 2021, they joined Atlas Newco as the Senior Director, Head of Chemistry, and in 2022, they moved to Rectify Pharma as the Senior Director, Medicinal Chemistry.

Nathan Fuller received their Bachelor of Science (B.S.) in Chemistry from The University of Massachusetts at Amherst in 2000. Nathan then continued their education, earning their Doctor of Philosophy (Ph.D.) in Chemistry from The University of North Carolina at Chapel Hill in 2005.